H1 2024 revenue
Half-yearly activity• H1 revenue: €419.2m, up 11.8% at CER1, including an acceleration in Q2(+14.5%)• This acceleration was driven by continued catch-up in the Americas, thenormalisation of orders in France and MRI sales

Annual targets confirmed• Revenue: expected growth of over 8% like-for-like and at CER• Profitability: restated EBITDA margin rate2 higher than in 2021 (14.4%)

Villepinte, 25 July 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agentsand solutions for medical imaging, is publishing its revenue for first-half 2024. As of June 30th, 2024, theGroup’s sales totalled €419.2m, up 10.7% compared with the same period in 2023 (€378.6m). Earnings
reflected a negative forex effect of €4.1m. At constant exchange rates (CER 1), Guerbet’s growth over thefirst six months was 11.8%. This trend includes an acceleration in the second quarter (+14.5% at CER),
following what was already a highly positive momentum in the first quarter (+8.8%).
Geographical breakdown of consolidated Group revenue (IFRS)In millions of euros,
at 30 June 2024

H1 2023*

H1 2024% change

H1 2024
At CER1% change

Sales in EMEA

178.5

183.4+2.7%

182.8

+2.4%

Sales in the Americas

98.6

127.3

+29.2%

127.2+29.1%

Sales in Asia

101.5

108.5

+6.8%

113.2

+11.5%

Total

378.6

419.2

+10.7%

423.3+11.8%

1

Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of theexchange rates used for the previous financial year.
2Restated EBITDA margin rate: excluding non-recurring costs related to the optimisation of the operating plan and changes inthe sales model.

Contacts:Guerbet
Jérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com
ActifinMarianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

1

In the EMEA region, Group revenue amounted to €183.4m in the first half, up 2.4% at CER. The decline
in the first quarter (-6.2% at CER) was fully offset in the second (+11.0% at CER) as business returned tonormal in France after the disruptions linked to the March 1st 2024 reform of the supply circuit for contrast
products.
Guerbet revenue in the Americas caught up strongly for the third consecutive quarter, with growth of
37.4% in the second quarter at CER, reflecting record production levels at the Raleigh site in North
Carolina. Total H1 revenue in the Americas came out at €127.3m, up 29.1% at CER.
Asia posted growth of 6.8% over the period, at €108.5m, including a persistent negative currency effect.
At CER, growth totalled 11.5% in the first half, despite a slowdown in the second quarter stemming fromthe contraction in sales in South Korea, where access to care has been paralysed since mid-February byan unprecedented doctor strike.

Breakdown of consolidated Group revenue (IFRS) by activity
In millions of euros,
at 30 June 2024

H1 2023*

H1 2024% change

H1 2024
At CER1% change

Diagnostic Imaging

336.5

368.8

+9.6%

372.3

+10.7%MRIX-ray

125.0
211.4

131.1

+4.8%

237.7

+12.4%

131.5
240.8

+5.2%
+13.9%

Interventional Imaging

42.2

50.4

+19.5%

50.9+20.8%

Total

378.6

419.2

+10.7%

423.3+11.8%

Diagnostic Imaging revenue amounted to €368.8m in H1 2024, up 10.7% at CER.
oMRI sales increased 5.2% at CER in the first half of the year thanks to a solid performance in thesecond quarter (+13.5%). Over this period, business was driven by a strong performance by theMRI franchise, and particularly the development of Elucirem TM in the United States, together with
the initial sales in Germany.

oX-ray revenue grew 13.9% at CER in H1 2024 as part of a positive business dynamic fuelled bysales of Xenetix® and Optiray®.

In Interventional Imaging, revenue at mid-year was up 20.8% at CER. This remarkable performancereflects a strong pick-up in the second quarter (+33.8% at CER) on continued positive momentum for
Lipiodol®, in terms both of volumes and prices.

Contacts:
GuerbetJérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com
ActifinMarianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

2

Solid visibility for H2 - Confirmation of financial targets for 2024
Having achieved a sustained growth trajectory in the first half of the year, Guerbet enters the second halfin full peace of mind. Beyond the catch-up in sales in the Americas, business continues to benefit fromfirmly established growth drivers firmly across the entire portfolio: in X-rays (Optiray® in particular),Interventional Imaging (strong momentum with Lipiodol ®) and the MRI franchise. The latter is now
reinforced by the expansion in Europe of Elucirem TM, which, after receiving an extremely favourable
reception in Germany in Q2 2024, will be launched in in the UK and France in the second half.
Guerbet also remains confident in improving its operating profitability, driven by the adjustment of theproduct mix and price increases, and in its ability to bring cash generation into positive territory.
Given these circumstances, the Group is confirming its forecast of sales growth of over 8% in 2024 likefor-like and at CER and expects its adjusted EBITDA margin rate to exceed that of 2021 (14.4%). Free
cash flow is expected to be in positive territory for the full year.

Next event:Publication of 1st half 2024 results
25 September 2024 after market close

About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are aleader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices,and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 97 years, withmore than 2,920 employees worldwide, we continuously innovate and devote 10% of our sales to research anddevelopment in four centres in France, the United States and Israel. Guerbet (GBT) is listed on Euronext Paris(segment B – mid caps) and generated €786 million in revenue in 2023.

Forward-looking statements
Certain information contained in this press release does not reflect historical data but constitutes forward-lookingstatements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but
not limited to assumptions about the current and future strategy of the Group and the economic environment in which
the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in asignificant difference between the Group’s actual performance and results and those presented explicitly or implicitly
by these forward-looking statements.
These forward-looking statements are valid only as of the date of this press release, and the Group expressly
disclaims any obligation or commitment to publish an update or revision of the forward-looking statements containedin this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The
forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking

Contacts:
GuerbetJérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com
ActifinMarianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

3statements and information are not guarantees of future performance and are subject to risks and uncertainties thatare difficult to predict and are generally beyond the Group’s control.

These risks and uncertainties include but are not limited to the uncertainties inherent in research and development,
future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatoryauthorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether
and when to approve any application for a drug, process, or biological product filed for any such product candidates,
and their decisions regarding labeling and other factors that may affect the availability or commercial potential ofsuch product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can befound in Chapter 4.9 “Risk factors” of the Group’s Universal Registration Document filed with the AMF (Frenchfinancial markets authority) under number D.24-0224 on April 3, 2024, available on the Group’s website(www.guerbet.com).

Contacts:
GuerbetJérôme Estampes, Chief Financial Officer +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Communications +33 6 30 11 57 82 / christine.allard@guerbet.com
ActifinMarianne Py, Financial Communications +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

4